secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-212548
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q2 net loss $34.9M; restructures with 35% workforce cut
--------------------------------------------------------------------

- Cash, equivalents, marketable securities $703.8M as of June 30, 2022; runway through 2028.
- R&D expense $28.9M (up 106% YoY), G&A $8.9M (up 39% YoY) on higher headcount and stock comp.
- Phase 1 monotherapy dosing underway for BET inhibitor NUV-868 in advanced solid tumors.
- Appointed Dr. David Liu as CMO (July) and Kerry Wentworth as CRO (May) to Executive Committee.
- Restructuring announced Aug 1, reducing workforce by 35% to cut costs and align with re-prioritized pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/0001193125-22-212548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312522212548/d312793d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-212548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer